



Usage of Neuroimaging Biomarkers Alzheimer's Disease for Assessment

Raja Prabhu*

Doctor of Pharmacy, Acharya Nagarjuna University, India

Mini Review

Alzheimer's disorder (AD) is one of the major reason of dementia amongst human beings nearly 60 years and older [1]. The main medical characteristic of AD is growing impairment accompanied via various ways of impairment of different cognitive domains, a function pathological cortical and hippocampal atrophy, histological characteristic of senile plaques of amyloid deposits and neurofibrillary tangles which includes intraneuronal tau neurofibrillary tangles [2]. The occurrence of AD is predicted to rise dramatically because of the population around the world which continues to age. Better knowledge of this disorder is required; therefore it is essential, and necessary to maintain early analysis mixed with a complete control method initiated early along the direction of the cognitive decline will be the simplest approach of controlling the development of AD [3].

Currently one of the foremost pushbacks toward accomplishing that is the issue in early and definitive analysis of AD [4]. Over the decade there was an exquisite quantity of studies output regarding the discipline of biomarkers of AD. In this opinion we have reviewed the structural MRI research which includes PET and SPECT which are being broadly researched along with the analysis of AD [4, 5]. Structural and purposeful imaging can be beneficial for the early analysis of AD [6, 7]. With growing studies in disorder editing remedy in AD and popularity of moderate cognitive impairment (MCI) as a totally incipient level of AD, early analysis of AD will help in early initiation of disorder editing remedy. These will be resourceful in enhancing the life of existence of people with AD.

Biomarkers have diagnostic and prognostic value in the early detection of AD [8]. Research on a wide range of biomarkers related to AD is developing. Among these, neuroimaging has the potential to predict the transition from MCI to AD [9]. Various brain imaging modalities are commonly used to study the neuropathological processes and morphological and functional changes that occur in AD [10, 11]. Neuroimaging is not only useful for early detection, but also for distinguishing AD from other neurodegenerative diseases [12]. Studies have shown that imaging can be used to predict the conversion of MCI to AD. Neuroimaging techniques can be primarily classified structurally and functionally. The most important structural imaging methods are Computed tomography (CT) and magnetic resonance imaging (MRI) [5]. CT imaging technology provides high resolution and has the ability to distinguish between the two structures separately. However, due to its high spatial resolution, MRI imaging techniques can be used to distinguish between two tissues that are arbitrarily similar but not identical. Other techniques such as positron emission tomography (PET), single photon emission computer tomography (SPECT), and functional MRI (fMRI) are examples of functional neuroimaging techniques. Functional imaging provides some structural information, but their spatial resolution is lower than that of structural imaging techniques.

Imaging Techniques used in diagnosis

Computed tomography (CT)

CT is not used as a standard technique for early diagnosis of AD but

*Corresponding author: Raja Prabhu, Doctor of Pharmacy, Acharya Nagarjuna University, India, E-mail: raj530230@gmail.com

Received: 2-Jun-2022, Manuscript No: cnoa-22-67700; **Editor assigned:** 6-Jun-2022, Pre-QC No: cnoa-22-67700 (PQ); **Reviewed:** 21-Jun-2022, QC No: cnoa-22-67700; **Revised:** 24-Jun-2022, Manuscript No: cnoa-22-67700 (R); **Published:** 30-Jun-2022, DOI:10.4172/cnoa.1000142

Citation: Prabhu R (2022) Usage of Neuroimaging Biomarkers Alzheimer's Disease for Assessment. Clin Neuropsychol, 5: 142.

Copyright: © 2022 Prabhu R. This is an open-access article distributed under the

many technologies available, CT head scan and structural MRI imaging are the most useful, widely available and affordable imaging modalities.

Acknowledgement

None

Conflict of Interest

None

References

1. Bischof J, Busse A, Angermeyer MC (2002) Mild cognitive impairment – a review of prevalence, incidence and outcome according to current approaches. *Acta Psychiatr Scand* 106: 403-414.
2. Humpel C (2011) Identifying and validating biomarkers for Alzheimer's disease. *Trends Biotechnol* 29: 26-32.
3. Wattamwar PR, Mathuranath PS (2010) An overview of biomarkers in Alzheimer's disease. *Ann Indian Acad Neurol* 13: S116–S123.
4. Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, et al. (2010) Comparing predictors of conversion and decline in mild cognitive impairment. *Neurology* 75: 230-238.
5. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, et al. (2005) Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. *J Neurosci* 25: 7709-7717.
6. Ortiz-Teran L, Santos JMR, Cabrera Martin MDL, Ortiz Alonso T (2011) Currently available neuroimaging approaches in Alzheimer's disease early diagnosis. In: De La Monte S, editor. *The clinical spectrum of Alzheimer's disease - The charge toward comprehensive diagnostic and therapeutic strategies*. New York: InTech 147-180.
7. Masdeua JC, Zubietab JL, Javier A (2005) Neuroimaging as a marker of the onset and progression of AD. *J Neurol Sci* 236: 55-64.
8. Hampel H, Frank R, Broich K, Teipel S, Katz R, et al. (2010) Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. *Nat Rev Drug Discov* 9: 560-574
9. Westman E, Simmons A, Zhang Y, Muehlboeck JS, Tunnard C, et al. (2011) Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls. *Neuroimage* 54: 1178-1187.
10. Wolz R, Julkunen V, Koikkalainen J, Niskanen E, Zhang DP, et al. (2011) Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease. *PLoS One* 6: e25446
11. Perrin RJ, Fagan AM, Holtzman DM (2009) Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. *Nature* 461: 916-922.
12. Walhovd KB, Fjell AM, Brewer J, McEvoy LK, Fennema-Notestine C, et al. (2010) Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. *Am J Neuroradiol* 31: 347-354.
13. Desikan RS, Cabral HJ, Christopher P, Dillion W, Glastonbury C, et al. (2009) Automated MRI measures identify individuals with MCI and AD. *Brain* 132: 2048-2057.
14. Devanand DP, Bensal R, Liu J, Hao X, Pradhaban G, et al. (2012) MRI hippocampal and entorhinal cortex mapping in predicting conversion to AD. *Neuroimage* 60: 1622-1629.
15. Devanand DP, Pradhaban G, Liu X, Khandji A, De Santi S, et al. (2007) Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. *Neurology* 68: 828-836.
16. Duchesne S, Caroli A, Geroldi C, Barillot C, Frisoni GB, et al. (2008) MRI-based automated computer classification of probable AD versus normal controls. *IEEE Trans Med Imaging* 27: 509-520.
17. Frisoni GB, Fox NC, Clifford R, Jack CR Jr, Scheltens P, et al. (2010) The clinical use of structural MRI in AD. *Nat Rev Neurol* 6: 67-77.
18. Vemuri P, Gunter JL, Senjem ML, Whitwell J, Kantarci K, et al. (2008) Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. *Neuroimage* 39: 1186-1197.
19. Zhang L, Chang R, Chu L-W, Mak K-F (2012) Current neuroimaging techniques in Alzheimer's disease and applications in animal models. *Am J Nucl Med Mol Imaging* 2: 386-404.
20. Ferreira LK, Busatto GF (2009) Neuroimaging in Alzheimer's disease: current role in clinical practice and potential future applications. *Clinics (Sao Paulo)* 66: 19-24.
21. Fennema-Notestine C, Hagler DJ Jr, McEvoy LK, Fleisher A, Wu EH, et al. (2009)